anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Claimed is the application of complementary peptides in oncology and cardiology. Potentially (i) a substance VPH (NH2 - Leu alpha N-Me-Phe Tyr Lys AlphaN-Me-Lys Val D-Tyr-COOH is anti-neoplastic; (ii) variation of the prim. structure of the peptide mimetic of calcium (Dillon, J. et al, Proc. Natl. Acad. Sci USA 88, 9726-9729) is an agent for hypertension or for tumours by inactivating the multi drug resistance gene prod.; (iii) peptide hSNI(B16-21) (3&#39;-5&#39;, NH2 - Leu-Pro-Thr-His-Asp-Ala-COOH) is useful in diseases including tumours which occur together with insulin hyperproduction, and (iv) complementary proteins to insulin and insulin growth factors I and II are similar to the complementary peptides of oncoprotein E7 of the human papilloma virus type 16 and to the complementary peptides of the binding proteins binding to the retinoblastoma (RB) protein which regulates cell growth. Therefore, these proteins may be competitors for the RB-protein binding site, pref. binding RB protein 649-654. USE - The complementary peptides are administered to cancer patients as a potentially more potent anti-cancer agent which also shows fewer side effects than known agents. In the case of treatment of hypertension the suggested peptide mimetic of calcium could be an alternative to known calcium antagonists.
PURPOSE:To attain the titled safe pharmaceutical of high quality, by dry heat- treating a human fibrinogen pharmaceutical in the presence of a disaccharide or sugar alcohol which is a stabilizer to inactivate hepatitis virus, etc., without deteriorating the fibrinogen pharmaceutical. CONSTITUTION:A human fibrinogen pharmaceutical is dried to 0.05-3%, preferably &lt;=1% moisture content and heat-treated in the presence of a disaccharide, e.g. white sugar or maltose, or sugar alcohol, e.g. D-sorbitol or D-mannitol, as a stabilizer. The above-mentioned stabilizer in an amount of 1-2g based on 1g human fibrinogen is preferably added. Furthermore, sodium citrate which is a conventional stabilizer is preferably used together. The heating is preferably carried out at about 60 deg.C for 65-90hr. Viruses can be inactivated and water solubility and solution properties of the resultant pharmaceutical can be improved without deteriorating the human fibrinogen.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine useful for the improvement of hypotension after a meal or the prevention of a disease or a state capable of being induced by the hypotension after the meal.  &lt;P&gt;SOLUTION: This improving agent of the hypotension occurring after the meal in a subject having a normal blood sugar value, patient with disease such as neuropathy or heart diseases, etc., elderly person or normal person (e.g. hypotension after the meal) containing an α-glucosidase inhibitor is provided. Also, the preventing agent of the disease or state (e.g. dizziness, faint, myocardial infarction and cerebral infarction) induced by the hypotension after the meal, containing the α-glucosidase inhibitor is also provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ameliorant for visual function disorder useful for ameliorating visual function disorders and a protective agent for optic nerve cells useful for protecting optic nerve cells.  &lt;P&gt;SOLUTION: The ameliorant for visual function disorder and the protective agent for optic nerve cells each comprises a propolis extract or a compound contained in a propolis original lump as an active ingredient. The active ingredient is preferably an extract of propolis with water, an alcohol extract or a water-containing alcohol extract. The ameliorant for visual function disorders ameliorates visual function disorders especially caused by reduction in function of optic nerve cells. The protective agent for optic nerve cells exhibits protection action especially on retinal ganglion cells and is useful for treating or preventing eye diseases. Retinal diseases such as retinal vessel occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, pigmentary degeneration of the retina, Leber&#39;s disease, glaucoma, etc., may be cited as the eye diseases.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
A pharmaceutical preparation having a tranquillizing effect on humans and animals in dosage unit form for oral, rectal or parenteral administration, comprising one or more solid or liquid pharmaceutical diluents or carriers and an active component consisting of an oxazoline derivative having the general structural formula &lt;FORM:0957297/A5-A6/1&gt; or a non-toxic pharmaceutically acceptable acid addition salt thereof, wherein R is a phenyl group optionally substituted by at least one 1 to 4 carbon alkyl group.  Injections contain at least 0.1% and oral preparations 0.25% of the active component.  The preparation may take the form of tablets, capsules, cachets, powders, pills, sterile solutions, suspensions and suppositories. Other compatible drugs such as phenacetin may be present. Specified oxazolines are 2-phenyl-4 : 4-bis - hydroxymethyl oxazoline and 2-(41-methylphenyl) - 4 : 4 - bis - hydroxymethyl oxazoline.  Tablets containing 2-phenyl-4,4-bis-hydroxymethyl oxazoline hydrochloride and phenacetin are disclosed.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a styling composition wherein an elastic cationic polyurethane is contained in a medium essentially comprising water.  &lt;P&gt;SOLUTION: The styling cosmetic composition contains at least one elastic cationic polyurethane in the cosmetically acceptable medium essentially comprising water. A cosmetic treatment method for shaping or keeping a hairstyle comprises the use of the cosmetic composition. The cosmetic composition is used for achieving hair shaping which is persistent over a long period of time or resistant to water. The polyurethane used in the composition is a fixing polyurethane which forms a non-adhesive, non-brittle film and enables plastic or elastic deformation.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
1358734 Concentrating &amp;c influenza virus SOUTH AFRICAN INVENTIONS DEVELOPMENT CORP 16 Aug 1971 [14 Aug 1970 30 Dec 1970] 38317/71 Heading A5B Influenza virus is obtained in a concentrated and purified form from an aqueous suspension thereof by adding to the suspension up to 5% by weight of polyethylene glycol (PEG) of M.W. 3000 to 20000 or an equivalent linear, filamentary, uncharged water-soluble polymer such as dextran, other polyalkylene glycols, poly 1, 4-dihydroxy butane glycol, nonylphenol-ethoxylate, polyvinyl alcohol or polyvinyl pyrrolidone and separating the insolubilized material. Under certain conditions, the virus is obtained in a dense, &#34;intimately aggregated&#34;- form in which the virus is in strongly coherent clusters in which individual particles may be disrupted, e.g. to release nucleic acids, without disruption of the aggregate. In a modification of the process, PEG is added up to 1% by weight and the resultant is subjected to phase separation to separate a protein-rich and protein-poor phase. The former is separated and the residual matter is treated with further PEG to a concentration at least 1% higher to produce another protein-rich fraction, either the protein-rich or protein-poor material being useful. The purified virus may be used for making vaccines.
FIELD: medicine. ^ SUBSTANCE: method for producing biocide consists in Na-form bentonite activation by sodium ions by means of processing with an aqueous solution of sodium chloride followed by chlorine anion removal with washing and filtration of the prepared raw material. Thereafter, the prepared raw material is intercalated by bactericidal metal ions by processing of inorganic salts in aqueous solutions: silver nitrate, copper sulphate, zinc sulphate or nitrate; sodium salts are removed by washing of the biocide product with deionised water; then the product is filtered, dried and grinded to particle size 20-150 nm. The activation and intercalation processes are performed by exposure to ultrasound at frequency 20-50 kHz and intensity 10-100 Wt/cm2, and the purification process of the intercalated product from sodium salts is two-staged: at first, the product is decanted, and then washed in deionised water containing 30 &#34;ppm&#34; - 100 &#34;ppm&#34; of an alkaline metal ion complexing agent of crown-ethers of molecular weight 264 and less. ^ EFFECT: production of biocide exhibiting fungicidal and bactericidal efficacy and used in preparations, compounds, compositions. ^ 6 cl, 6 ex, 1 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new sugar alcohol powdery composition for tableting without requiring treatments such as granulation, etc., capable of directly tableting at a low pressure, and also capable of reducing the amount of lubricant blended in the tablets, also the tablets or confectionery tablets obtained by tableting the powdery composition and a method for producing the same.  &lt;P&gt;SOLUTION: This sugar alcohol powdery composition consisting of a crystalline component and an amorphous component contains 2-12 wt.% amorphous sorbitol. The sugar alcohol powdery composition can be used as an excipient of the tablet or tablet-formed confectioneries. By mixing the sugar alcohol powdery composition, a lubricant and a food material or a medicinal active ingredient, the mixture is formed as tablets. The method for producing the tablets or confectionery tablets by tableting the mixture and also the tablets or confectionery tablets obtained by the method are also provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition useful for preventing or treating autoimmune diseases, especially Sjogren&#39;s syndrome, by including α- fodrin (mutein), their fragment proteins, or their salts as active ingredients. SOLUTION: This composition contains α-fodrin (mutein), their fragment proteins or their salts. The α-fodrin (mutein), their fragment proteins or their salts include human α-fodrin protein. The protein containing human α-fodrin portion sequence, especially an amino acid sequence of the formula, and having a mol.wt. of 2-240K is preferable. The mutein of the α-fodrin includes proteins in which the mutation, substitution, etc., of one or more amino acids are caused, so long as the amino acids constituting the α-fodrin do not lose their immunological values. The α-fodrin fragment proteins include fragmented proteins produced on the degradation of the α-fodrin with a protease, etc.
The invention discloses a medicated bath prescription for treating psoriasis and a preparation method therefor. The medicated bath prescription is composed of raw materials comprising 20-25g of Xing&#39; an sabina chinensis branches and leaves, 20-25g of Myricaria laxiflora, 20-25g of rhododendrons, 20-25g of wedelia prostrate, 20-25g of rutaceae, 20-25g of white sesame seeds, 20-25g of radix asparagi, 20-25g of cassia occidentalis, and 5-10 parts of musk water. The preparation method comprises the following steps: parts of the above raw materials are subjected to fermentation and then are dried; the other raw materials are added, the mixture is boiled, a liquid is obtained after filtration, and the liquid is added during bath. During medicated bath, trichopores can be opened in a water temperature, and therefore diseases can be expelled from a body. In addition, the opened trichopores facilitate effective components of the medicine to go into the body easily, so the effects of the therapy are obvious and rapid. In addition, The medicated bath method has good effects on treatment of rheumatism, grasserie, traumatic injury and the like.
The present invention relates to treatment of age-related diseases. The inventors have compared the hematopoietic phenotype of one constitutive knockout (Rinf/_) and one conditional knockout (Vav-Cre+/-Rintf ox/flox) mouse model specifically invalidated in the hematopoietic tissue for Cxxc5. Accelerated aging of hematopoietic cells in Rinf/_ mouses but unexpectedly not in Vav-Cre+/&#39;Rinfflox/flox mouses revealed a key role of Rinf in the BM niche and that the Rinf/- mouse can be used as a model for age-related diseases. They identified the cytokine G-CSF as particularly deregulated and highly expressed in the BM microenvironment of Rinf/- animals. They showed that in vivo targeting of G-CSF with a depleting antibody resolved lymphopenia and neutrophilia. The invention relates to a G-CSF inhibitor for use in the treatment of age-related diseases in a subject in need thereof.
555,044. Treating silk prior to pulverizing. PHELPS, S. G. Jan. 28, 1942, No. 1205. [Class 59] [Also in Groups VI and IV] In the preparation of powdered silk for use as a cosmetic and for application in ointments &amp;c. the material is first boiled in a weak solution of lauryl sulphate, washed with cold water, heated slowly with dilute sulphuric acid, borax is then added, the mixture allowed to cool and liquid drained off, fresh water added to the silk and boric acid and brought to the boil. The liquid is strained from the silk which is dried at 85 ‹F. and pulverized.
An ionisable basic or acid therapeutic agent is reacted respectively with a cation or anion exchange resin having a degree of cross linking in the ranges of 1-5 or 7-9 % or of 12 or 20% and a particle size between -16 and +200 mesh B.S.S., to give a therapeutic composition suitable for oral administration.  The product may be admixed with uncombined resin.  The resin may be &#34;Zeokarb&#34; (Registered Trade Mark) 225 or 226 or &#34;De Acidite&#34; (Registered Trade Mark) E or FF.  The basic therapeutic agent may be ephedrine or amphetamine and the acid one may be an acid, aspirin or a barbituric acid derivative.ALSO:An ionisable basic or acid therapeutic agent is reacted respectively with a cation or anion exchange resin having a degree of cross linking in the ranges of 1-5 or 7-9% or of 12 or 20% and a particle size between -16 and +200 mesh, BSS., to give a therapeutic composition suitable for oral administration.  The product may be admixed with uncombined resin.  The resin may be &#34;Zeokarb&#34; (Registered Trade Mark) 225 or 226 or &#34;DeAcidite&#34; (Registered Trade Mark) E or FF.  The basic therapeutic agent may be ephedrine or amphetamine and the acid one may be an acid, aspirin or a barbituric acid derivative.
A medical delivery device is provided for delivering a medicinal substance into a user&#39;s body. An upper assembly includes a housing having a cavity configured for accommodating a needle. A lower assembly includes a receptacle member having an opening configured for accommodating insertion of the upper assembly, and a base member having an upper body and a recess formed on a top surface of the upper body for receiving the receptacle member. A base pad has an adhesive layer disposed on a lower surface of the pad, and being at least partially attached to a bottom side of the base member. The lower assembly is attached to a skin of the user using the base pad. As the upper assembly transitions from an upper position to a lower position relative to the lower assembly, the needle travels downwardly to penetrate the skin for facilitating administration of the medicinal substance.
An immuno-stimulating glycopeptide, obtd. from the cell wall of an immunity stimulating bacterium of the Actinomycetaceae or Mycobacteriaceae genus (Prevot&#39;s classification), is purified by removing nucleic acids and Cytoplasma proteins, pref. by treating the whole bacterial cells by 2-phase extraction using aq. and aryl alcohol contg. phases. A novel immuno-stimulating glycopeptide (I), obtd. from cell walls of a suitable immuno-stimulating Actinomycetaceae or Mycobacteriacease bacterium, is insol. in water, physiolocial saline, MeOH, EtOH, PhOH, CHCL3, dioxan, pyridine, DMF, diethylene glycol and hexane; is free of nuclei acids; has IR absorptions at 1550 and 1660 cm -1 (due to peptide) and at 950-1100 cm -1 (max. 1050-1070 cm -1) (due to carbohydrate); has little or no lipid absorption at 2850-2950 cm -1; and on i.v. admnistration increases the wt. of the liver and spleen of mice, and increases the life expectancy of mice infected with tumours. (I) increases the resistance of animals and birds to tumours and various disease stimulants, by inhibiting growth and/or preventing the start of growth. (I) may be used therapeutically or prophylactically against tumours such as leukaemia, Hodgknson&#39;s disease, carcinoma of the lungs, bladder or breast, melanoma and Burkitt&#39;s lymphoma, against bacterial diseases due to Bordetella pertussis or Brucella abortus, or against parasitic protozoal diseases e.g. malaria.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an immunostimulation composition which includes fucoidan and lactobacillus, and has a high IL-10 production promotion action.  &lt;P&gt;SOLUTION: Fucoidan derived from Undaria pinnatifida of 0.1-10 pts.wt. is added to lactic acid bacterium, based on 1 pt.wt. of fungus belonging to genera Tetragenococcus, Pediococcus, Lactobacillus or the like, and is cultivated, thereby the immunostimulation composition having an IL-12 production promotion action and also a high IL-10 production promotion action can be obtained. The immunostimulation composition is anticipated to have a high effect in ameliorating a symptom of I type allergy or a symptom relaxation of ulcerative colitis or the like which is an inflammatory disease.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic tool for athlete&#39;s foot widely or sufficiently sterilizing/exterminating bacteria of athlete&#39;s foot by deeply penetrating from corneal layer of epidermis to dermis through cuticle to eradicate the athlete&#39;s foot and inhibit recurrence of the disease.  &lt;P&gt;SOLUTION: The therapeutic agent for athlete&#39;s foot 4 comprises an extract obtained by blewing the bark of Hibiscus syriacus in hot water, and an alcohol which is easy to permeate from the skin. An inner sock 9 to which the therapeutic agent 4 permeates easily and widely and entirely penetrates by a capillary phenomenon, is put on the foot. A bag 8 with chemical liquid impermeability is applied on the outside of the inner sock 9, and the therapeutic liquid 4 is filled in the bag and the mouth of the bag 8 is tightly closed by a rubber band 6, the therapeutic liquid for athlete&#39;s foot 4 is not permeated, vaporized and leaked. An outer sock 7 is applied on the outside of the bag 8, the bag 8 with chemical liquid impermeability is constricted from outside and the therapeutic agent liquid 4 is raised up to a therapeutic agent liquid 4 raising level 2.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: A GABA(gamma-aminobutyric acid) release inhibitor containing bestrophin 1 channel inhibitor is provided to enable effective and various treatment for GABA-associated disease symptom. CONSTITUTION: A composition for preventing or treating diseases or symptom due to GABA excessive release contains bestrophin 1 channel inhibitor as an active ingredient. The composition suppresses GABA release in the bovine cerebellum. The bestrophin 1 channel inhibitor is an antisense RNA or shRNA of a nucleotide sequence encoding an anion channel blocker and bestrophin 1 channel. The anion channel blocker is niflumic acid, 5-nitro-2(3-phenylpropylamino)-bazoic acid(NPPB) or 4,4&#39;-diisothiocyanatostylbene-2,2&#39;-disulfonic acid(DIDS). The nucleotide sequence encoding the bestrophin 1 channel is a sequence of sequence number 1 or 2. A composition for preventing or treating diseases due to GABA deficiency contains a bestrophin 1 channel activator as an active ingredient. The activator is a peptide TFLLR and Bradykinin.
Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compounds are selective for sphingosine kinase type 2 relative to sphingosine kinase type 1. Compounds of the invention can be used in treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. Diseases that can be treated by administration of an effective dose of a compound of the invention include a neoplastic disease that involves excess vascular growth; macular degeneration or diabetic retinopathy; an allergic disease such as asthma, an inflammatory disease of the eye such as uveitis, scleritis, or vitritis; an inflammatory disease of the kidney; a fibrotic disease; atherosclerosis; or pulmonary arterial hypertension. A compound of the invention can be used to improve the integrity of a vascular barrier in a disease where the vascular barrier is disrupted, such as cancer or Alzheimer&#39;s disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for controlling the expression of SMN gene.  &lt;P&gt;SOLUTION: A nucleic acid for a splicing control factor or a variant thereof comprising a specific base sequence is provided. A nucleic acid-introducing carrier containing the nucleic acid is provided. The method for controlling the expression of SMN gene using the nucleic acid is provided. A pharmaceutical composition containing the nucleic acid or the carrier as active ingredient is provided. A method for retrieving a splicing-enhancing substance for SMN gene&#39;s exon 7 is also provided, comprising the following steps: in the presence/absence of a specimen, a cell is maintained which contains an exon trap vector construct operably bound with a nucleic acid construct comprising SMN2 gene&#39;s intron 6, SMN2 gene&#39;s exon 7 and SMN2 gene&#39;s intron 7 containing a nucleic acid for a splicing control element comprising a specific base sequence, and the amount of a transcription product corresponding to the SMN2 gene&#39;s exon 7 in the cell obtained in the presence of the specimen and the amount of a transcription product corresponding to the SMN2 gene&#39;s exon 7 in the cell obtained in the absence of the specimen are measured.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Compositions discussed herein are useful for treating a patient infected with a coronavirus, notably SARS-CoV-2 or COVID-19. The compositions to be administered to an infected patient utilize inhibitors of SARS-CoV-2 papain-like protease (PL pro ). Several of these inhibitors include available hepatitis C virus (HCV) drugs that are already FDA-approved. These PL pro  inhibitors have been found to be strongly synergistic with inhibitors of SARS- CoV-2 polymerases, such as RNA-dependent RNA polymerase (RdRp). One such polymerase inhibitor, remdesivir, is already in use as an anti-viral treatment of patients with COVID-19. The PL pro  inhibitors, including repurposed HCV drugs such as grazoprevir, vaniprevir, and paritaprevir, increase remdesivir&#39;s ability to suppress coronavirus replication antiviral activity as much as 10-fold. These compositions can provide more effective patient therapies with less toxicity and side effects compared with the current standard of care, as well as enable outpatient treatment for COVID-19 with orally ingestible polymerase inhibitors such as molnupiravir (MK-4482/EIDD-2801).
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a dosage form which is comfortable with respect to its feeling of use.  &lt;P&gt;SOLUTION: The skin care preparation of emulsion dosage form comprises (1) an extract of fruit of Eugenia aromatica of the family Myrtaceae, (2) an organic-modified clay mineral and (3) an N-acylated (10-30C) glutamic acid dialkyl (1-30C) ester. Preferably the extract of fruit of Eugenia aromatica of the Myrtaceae is prescribed to have eugenol as an index substance. Preferably the eugenol content is 1-10 mass% based on the total of the extract. Preferably the fruit of the Eugenia aromatica of the Myrtaceae is extracted with an alcohol. Preferably the emulsion dosage form is an oil-in-water-in-oil emulsion dosage form.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT